MDL | MFCD08704648 |
---|---|
Molecular Weight | 448.58 |
Molecular Formula | C22H22Ca0.5NO4S2 |
SMILES | O=C(N(C[C@@H](SC1=CC=CC=C1)C2)[C@@H]2C([O-])=O)[C@H](C)CSC(C3=CC=CC=C3)=O.[0.5Ca2+] |
Zofenopril Calcium (SQ26991) is an antioxidant that acts as an angiotensin-converting enzyme inhibitor. Target: ACE Zofenopril Calcium is a pro-drug designed to undergo metabolic hydrolysis yielding the active free sulfhydryl compound zofenoprilat, which is an angiotensin converting enzyme (ACE) inhibitor [1]. Zofenopril Calcium promotes the regeneration of peripheral nerve injuries in rat models [2]. Zofenopril Calcium increases SR calcium cycling and stimulates active calcium uptake into the SR [3].
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT05257148 | Menarini International Operations Luxembourg SA |
Hypertension
|
April 28, 2021 | Phase 4 |
NCT05279807 | Menarini International Operations Luxembourg SA |
Hypertension
|
October 15, 2021 | Phase 4 |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
DMSO : 2 mg/mL ( 4.46 mM ; Need ultrasonic)
H 2 O : < 0.1 mg/mL (insoluble)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.2293 mL | 11.1463 mL | 22.2926 mL |
5 mM | --- | --- | --- |
10 mM | --- | --- | --- |